Audit: QRS - Estrogen for Health & Longevity

Audit conducted on 12/09/2026 12:22 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	85
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Protocol cells, gates, tier lists, all 12 monitoring rows, cadence and all 7 qualitative items trace to ER Therapeutic Protocol, Key Interactions & Contraindications, Expected Benefits, Potential Risks & Side Effects, Practical Considerations and Monitoring Protocol & Defining Success.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	No ER section is empty and no empty-state phrasing is carried over or invented.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindication strength preserved (“Known or suspected pregnancy” kept in the stop gate, not the caution gate); “Most clotting harm tracks oral dosing” is narrower, not stronger, than the ER conclusion.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	All caution items come from ER interaction bullets; no Benefit- or Risk-Modifying Factor (COMT, CYP1B1, APOE4, baseline triglycerides) is surfaced in a gate or risk tier.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS contains no PMIDs, citations, expert names, NCT identifiers or brand names.
1.6	The QRS does not introduce new attributions.	🟢	No attributions present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Neutral, evidence-first register matching the ER; tier headings reused verbatim.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Benefit and risk tiers are presented side by side with concrete targets and intervals, enabling an informed decision.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Protocol cells describe regimens (“Patch changed twice weekly”, “micronized progesterone 100 mg nightly where a uterus is present”) rather than instructing.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives directed at a patient; the footer disclaimer is the template’s own.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrence of “recommended”, “advised”, “should” in the document’s own voice.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Jargon retained only where it is the ER’s own term of art (e.g., “genitourinary syndrome of menopause”); the lede uses plain equivalents.
2.8	Information is presented in a concise and very compact manner	🟢	Benefit and risk tiers carry ER headings only; gate items are stripped to the key fact.
2.9	It DOES NOT address the reader directly	🟢	Confirmed: no direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Route-versus-risk distinction, functional biomarker targets and a 12-marker panel address a proactive, risk-aware reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Twice-weekly patches, nightly inserts, quarterly ring replacement and a multi-marker monitoring cadence assume willingness to follow effortful protocols.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplified “ask your doctor” framing; functional rather than conventional reference ranges are used.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The lede foregrounds the route distinction and the timing-of-initiation contraindication, which is where the longevity-oriented signal diverges from general-population messaging.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not occur; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	Route of administration is stated formally throughout, including in the lede (“oral dosing”, “low-dose vaginal preparations”, “Transdermal”, “Vaginal estradiol”); no “pill”, “taken by mouth” or “shot”.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All present byte-identical to [qrs_template] (lines 444, 484, 526, 551, 572, 598, 622, 626–628, 783).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 38 distinct template variable names present; 77 span instances (marker_# expanded to 12 rows, qualitative_item_# to 7 items).
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	A normalised diff against [qrs_template] shows no change outside variable spans; website="evidence_review", website="audit", website="full_review", the CSS block and the footer disclaimer are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section relied on by the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels “Standard regimen”, “Oral alternative”, “Local genitourinary regimen” are the ER bold labels verbatim (ER lines 433, 435, 437); monitoring row labels match the ER biomarker table verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Tier lists reuse ER sub-heading wording; no invented labels.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji in the file; the ER’s ⚠️ Conflicted markers are dropped and tiers carry bold text labels plus CSS colour only.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every discretionary surface is at minimum length (tier lists are headings only, gate items stripped to the key fact, marker targets and reasons reduced to a single clause); remaining length is fixed by the completeness requirements of 8.2, 9.2, 14.2 and 15.2.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14; the next comment is at line 16.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” at line 3, closing at line 13; the preamble text “QRS — Metadata (invisible, parsed by audit tooling)” precedes it.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment and not duplicated anywhere in the body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:04" is quoted, which is required by its colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: estrogen_2026-0912-0819_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.9.11, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0912-1209.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version only, no trailing qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file on disk: estrogen_2026-0912-0819_Opus_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Estrogen for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Estrogen for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 09/12/2026, matching qrs_creation_date 2026-0912.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header block (lines 415–428) is identical to the template apart from the three variable spans.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses ER lines 585 and 589: the three strongest benefits, the matching harms, and the route distinction.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a clause of ER line 585; “Most clotting harm tracks oral dosing” maps to “Most of the clotting and blood-vessel harm tracks the oral route rather than the hormone itself”.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	Uses “broken bones”, “tissue thinning”, “bladder infections”, “bladder leakage”, “womb lining” in place of fracture, atrophy, UTI, incontinence and endometrium; no acronyms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years or sample sizes.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No hazard ratios, odds ratios, confidence intervals or percentages.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All ten items come from ER lines 369 and 389–405.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All nine “Populations who should avoid Estrogen” bullets plus the ER’s one absolute contraindication (tamoxifen and aromatase inhibitors, ER line 369) are present.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Ten <li> elements inside the [stop_items] span (lines 554–567).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	No dashes carry trailing clauses; the ER’s em-dash construction for the arterial event was converted to parentheses, and the mechanistic sentence following “Absolute contraindication” was dropped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“at any interval since treatment”, “until evaluated histologically”, “within the preceding 12 months”, “Child-Pugh Class B or C”, “above 500 mg/dL (oral preparations specifically)”, “after age 65 or more than 10 years past menopause” all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	Parenthetical content is plain comma-separated (“myocardial infarction, ischaemic stroke”; “anastrozole, letrozole, exemestane”); no bare ranking symbols carried through.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names nine such populations plus one absolute contraindication, and the section is correspondingly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All twelve items come from ER lines 361–385.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Twelve of the ER’s thirteen interaction bullets are present; the excluded one (tamoxifen and aromatase inhibitors) sits in the Contraindications gate and is correctly not duplicated.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Twelve <li> elements inside the [caution_items] span (lines 575–588).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every item is the ER label alone; caution/monitor grades, mechanisms and mitigations are stripped, and the ER’s “Other interventions —” dash prefix is removed.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Named example drugs retained in full for the CYP3A4 inducers, CYP3A4 inhibitors, phytoestrogen and aromatase-inhibitor lists, plus “(over-the-counter)” for acetaminophen and “(DHEA)” for dehydroepiandrosterone.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	All parenthetical drug lists are plain comma-separated; no ranking symbols present.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names thirteen interactions and the section is correspondingly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from the first three bullets of the ER Therapeutic Protocol (ER lines 433–437).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Standard transdermal regimen, oral alternative and local genitourinary regimen are the only three implementation bullets in the ER protocol; the remainder are competing approaches, attributions and modifiers.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct actionable aspects and all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans carry ER-derived content: doses 0.025–0.1 mg/day transdermal, 0.5–1.5 mg/day gel, 0.5–2 mg/day oral, CEE 0.3–0.625 mg/day, vaginal estradiol 10 µg and the 7.5 µg/day ring all match the ER.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Hot flushes, bone density and genitourinary symptoms — the three intervals attached to the ER’s High-tier benefits (ER line 494).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Order matches the ER’s High-tier benefit order: hot flushes, fracture/bone, genitourinary syndrome.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies four intervals and all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	“2–4 weeks” / “Full response by twelve weeks”, “12 months”, “4–12 weeks” all match ER line 494.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information in Practical Considerations.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All twelve entries correspond one-to-one with the ER’s twelve benefit sub-headings (ER lines 151–225).
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated (lines 528–544) with 3, 5, 2 and 2 items respectively, matching the ER tier counts.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the ER sub-heading alone; no magnitudes, confidence intervals or mechanistic sentences carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits span.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers have items in the ER.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All fourteen entries correspond one-to-one with the ER’s fourteen risk sub-headings (ER lines 253–341).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated (lines 600–616) with 8, 4, 1 and 1 items respectively, matching the ER tier counts.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the ER sub-heading alone; hazard ratios and absolute rates from the ER Magnitude lines are omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks span; the ER’s expansions such as “(VTE, …)” are not carried over.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers have items in the ER.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Rows and cadence derive from the ER Monitoring Protocol & Defining Success biomarker table and ER line 526.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 12 ER biomarkers present in ER order with matching targets and reasons: estradiol, FSH, triglycerides, LDL cholesterol, Lp(a), SHBG, ALT, TSH, endometrial thickness, BMD T-score, hsCRP, blood pressure.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 774–777 reproduce the ER cadence: 6–8 week symptom and blood pressure review, 12-week labs then every 6–12 months, annual mammography, two-yearly densitometry, endometrial imaging on unscheduled bleeding.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All seven items come from the qualitative marker list at ER lines 545–557.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	7 of 7 present in ER order: hot flush count, sleep continuity, vaginal comfort, cognitive clarity, mood stability, joint stiffness, breast tenderness and bleeding.

Issues 12/09/2026 12:22

Pass rate 100.00%. No issues found.

Issues 12/09/2026 12:19

1. 12.3 / 12.4 — “(conflicted)” qualifier not stripped: Four benefit items carry the parenthetical evidence-strength qualifier “(conflicted)” — QRS lines 533, 534, 540 and 544 — although the tier label already encodes evidence strength and section 12 requires parenthetical content to be stripped.
2. 13.3 / 13.4 — “(conflicted)” qualifier not stripped: The [risks_medium] item “Coronary heart disease events with late initiation (conflicted)” at QRS lines 608–609 retains the same parenthetical qualifier, which section 13 requires to be stripped.

Fixes 12/09/2026 12:19

1. 12.3 / 12.4 — “(conflicted)” stripped from Benefits: Removed the four “(conflicted)” parentheticals from [benefits_medium], [benefits_low] and [benefits_speculative], leaving the bare ER sub-heading facts.
2. 13.3 / 13.4 — “(conflicted)” stripped from Risks: Removed the “(conflicted)” parenthetical from the coronary heart disease item in [risks_medium], leaving “Coronary heart disease events with late initiation”.

Issues 12/09/2026 12:13

1. 7.2 — At-a-glance exceeds word ceiling: The [at_a_glance] span at lines 433–437 runs to 62 words, exceeding the 60-word limit.
2. 11.4 — Skin fact under genitourinary cell: [time_3_sub] at line 518 states “Skin changes register at six months.” beneath the “Genitourinary symptoms” label, attaching an unrelated time-to-effect fact to that cell.

Fixes 12/09/2026 12:13

1. 7.2 — At-a-glance trimmed to 59 words: Condensed “when a second hormone is added to protect the womb lining” to “when a second hormone protects the womb lining”, bringing [at_a_glance] from 62 to 59 words.
2. 11.4 — Genitourinary time-to-effect sub: Replaced [time_3_sub] “Skin changes register at six months.” with “Interval for response to low-dose vaginal estrogen.”, so the sub matches its “Genitourinary symptoms” label.